690 related articles for article (PubMed ID: 29573965)
1. The evolution of bladder cancer genomics: What have we learned and how can we use it?
Audenet F; Attalla K; Sfakianos JP
Urol Oncol; 2018 Jul; 36(7):313-320. PubMed ID: 29573965
[TBL] [Abstract][Full Text] [Related]
2. Molecular Subtypes of Urothelial Bladder Cancer: Results from a Meta-cohort Analysis of 2411 Tumors.
Tan TZ; Rouanne M; Tan KT; Huang RY; Thiery JP
Eur Urol; 2019 Mar; 75(3):423-432. PubMed ID: 30213523
[TBL] [Abstract][Full Text] [Related]
3. Targeted DNA and RNA Sequencing of Paired Urothelial and Squamous Bladder Cancers Reveals Discordant Genomic and Transcriptomic Events and Unique Therapeutic Implications.
Hovelson DH; Udager AM; McDaniel AS; Grivas P; Palmbos P; Tamura S; Lazo de la Vega L; Palapattu G; Veeneman B; El-Sawy L; Sadis SE; Morgan TM; Montgomery JS; Weizer AZ; Day KC; Neamati N; Liebert M; Keller ET; Day ML; Mehra R; Tomlins SA
Eur Urol; 2018 Dec; 74(6):741-753. PubMed ID: 30033047
[TBL] [Abstract][Full Text] [Related]
4. Comprehensive Genomic Characterization of Upper Tract Urothelial Carcinoma.
Moss TJ; Qi Y; Xi L; Peng B; Kim TB; Ezzedine NE; Mosqueda ME; Guo CC; Czerniak BA; Ittmann M; Wheeler DA; Lerner SP; Matin SF
Eur Urol; 2017 Oct; 72(4):641-649. PubMed ID: 28601352
[TBL] [Abstract][Full Text] [Related]
5. Mutational Analysis of 472 Urothelial Carcinoma Across Grades and Anatomic Sites.
Nassar AH; Umeton R; Kim J; Lundgren K; Harshman L; Van Allen EM; Preston M; Dong F; Bellmunt J; Mouw KW; Choueiri TK; Sonpavde G; Kwiatkowski DJ
Clin Cancer Res; 2019 Apr; 25(8):2458-2470. PubMed ID: 30593515
[TBL] [Abstract][Full Text] [Related]
6. [Point somatic mutations in bladder cancer: key carcinogenesis events, diagnostic markers and therapeutic targets].
Mikhailenko DS; Nemtsova MV
Urologiia; 2016 Feb; (1):100-105. PubMed ID: 28247712
[TBL] [Abstract][Full Text] [Related]
7. Identification of potential therapeutic targets in urothelial bladder carcinoma of Chinese population by targeted next-generation sequencing.
Wang T; Liu Z; Wang X; Bai P; Sun A; Shao Z; Luo R; Wu Z; Zhang K; Li W; Xiao W; Duan B; Wang Y; Chen B; Xing J
Cancer Biol Ther; 2020 Aug; 21(8):709-716. PubMed ID: 32449441
[TBL] [Abstract][Full Text] [Related]
8. RB1 and TP53 co-mutations correlate strongly with genomic biomarkers of response to immunity checkpoint inhibitors in urothelial bladder cancer.
Manzano RG; Catalan-Latorre A; Brugarolas A
BMC Cancer; 2021 Apr; 21(1):432. PubMed ID: 33879103
[TBL] [Abstract][Full Text] [Related]
9. Molecular Subtypes of Bladder Cancer.
McConkey DJ; Choi W
Curr Oncol Rep; 2018 Aug; 20(10):77. PubMed ID: 30128829
[TBL] [Abstract][Full Text] [Related]
10. Bladder cancer genomics.
Siracusano S; Rizzetto R; Porcaro AB
Urologia; 2020 May; 87(2):49-56. PubMed ID: 31942831
[TBL] [Abstract][Full Text] [Related]
11. Morphologic and genomic characterization of urothelial to sarcomatoid transition in muscle-invasive bladder cancer.
Genitsch V; Kollár A; Vandekerkhove G; Blarer J; Furrer M; Annala M; Herberts C; Pycha A; de Jong JJ; Liu Y; Krentel F; Davicioni E; Gibb EA; Kruithof-de Julio M; Wyatt AW; Seiler R
Urol Oncol; 2019 Nov; 37(11):826-836. PubMed ID: 31585777
[TBL] [Abstract][Full Text] [Related]
12. Long non-coding RNAs identify a subset of luminal muscle-invasive bladder cancer patients with favorable prognosis.
de Jong JJ; Liu Y; Robertson AG; Seiler R; Groeneveld CS; van der Heijden MS; Wright JL; Douglas J; Dall'Era M; Crabb SJ; van Rhijn BWG; van Kessel KEM; Davicioni E; Castro MAA; Lotan Y; Zwarthoff EC; Black PC; Boormans JL; Gibb EA
Genome Med; 2019 Oct; 11(1):60. PubMed ID: 31619281
[TBL] [Abstract][Full Text] [Related]
13.
Weyerer V; Eckstein M; Strissel PL; Wullweber A; Lange F; Tögel L; Geppert CI; Sikic D; Taubert H; Wach S; Wullich B; Hartmann A; Stoehr R; Giedl J
Genes (Basel); 2021 Feb; 12(2):. PubMed ID: 33562516
[TBL] [Abstract][Full Text] [Related]
14. H-RAS mutation is a key molecular feature of pediatric urothelial bladder cancer. A detailed report of three cases.
Castillo-Martin M; Collazo Lorduy A; Gladoun N; Hyun G; Cordon-Cardo C
J Pediatr Urol; 2016 Apr; 12(2):91.e1-7. PubMed ID: 26522772
[TBL] [Abstract][Full Text] [Related]
15. Comparative Analysis of Differentially Mutated Genes in Non-Muscle and Muscle-Invasive Bladder Cancer in the Chinese Population by Whole Exome Sequencing.
Wang F; Dong X; Yang F; Xing N
Front Genet; 2022; 13():831146. PubMed ID: 35419031
[No Abstract] [Full Text] [Related]
16. Slow N-acetylation as a possible contributor to bladder carcinogenesis.
El Kawak M; Dhaini HR; Jabbour ME; Moussa MA; El Asmar K; Aoun M
Mol Carcinog; 2020 Sep; 59(9):1017-1027. PubMed ID: 32529781
[TBL] [Abstract][Full Text] [Related]
17. Identification of an immunotherapy-responsive molecular subtype of bladder cancer.
Song BN; Kim SK; Mun JY; Choi YD; Leem SH; Chu IS
EBioMedicine; 2019 Dec; 50():238-245. PubMed ID: 31735557
[TBL] [Abstract][Full Text] [Related]
18. Comparative bioinformatics analysis of prognostic and differentially expressed genes in non-muscle and muscle invasive bladder cancer.
Silva TA; Azevedo H
J Proteomics; 2020 Oct; 229():103951. PubMed ID: 32860965
[TBL] [Abstract][Full Text] [Related]
19. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
[TBL] [Abstract][Full Text] [Related]
20. Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.
Choi W; Ochoa A; McConkey DJ; Aine M; Höglund M; Kim WY; Real FX; Kiltie AE; Milsom I; Dyrskjøt L; Lerner SP
Eur Urol; 2017 Sep; 72(3):354-365. PubMed ID: 28365159
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]